ERBB2 and breast cancer: Furthermore, two studies (TRYPHAENA and TRAIN-2) examined neoadjuvant trastuzumab and pertuzumab-containing regimens for HER2 amplified, early-stage breast cancer and showed no significant difference in the rates of pCR or EFS with or without an anthracycline193–195.